Taiwan

Island
Taiwan-0xc6fd0 Favicons?domain=wwwCentre Daily Times | 1 hour ago

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread® for Chronic Hepatitis B in Key Asian Countries

...countries is greater than 8 percent. Under the agreement announced today, Gilead will retain exclusive rights for commercialization of Viread for HBV in Hong Kong, Singapore, South Korea and Taiwan. In China, GSK will have exclusive...

In this article: Gilead, GlaxoSmithKline, HBV, Tenofovir, Adefovir, Chronic hepatitis, Gilead Sciences, Asia, HIV, and Trademark

Connections-toggle
Filter by
or